Zevra Therapeutics, Inc. (ZVRA)
12.40
-0.14
(-1.12%)
USD |
NASDAQ |
Sep 04, 16:00
12.39
-0.01
(-0.08%)
After-Hours: 20:00
Zevra Therapeutics SG&A Expense (TTM) : 74.63M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 74.63M |
| March 31, 2026 | 78.85M |
| December 31, 2025 | 77.62M |
| September 30, 2025 | 73.39M |
| June 30, 2025 | 72.66M |
| March 31, 2025 | 64.48M |
| December 31, 2024 | 54.87M |
| September 30, 2024 | 53.40M |
| June 30, 2024 | 43.01M |
| March 31, 2024 | 37.02M |
| December 31, 2023 | 34.31M |
| September 30, 2023 | 24.43M |
| June 30, 2023 | 22.58M |
| March 31, 2023 | 19.53M |
| December 31, 2022 | 15.04M |
| September 30, 2022 | 12.82M |
| June 30, 2022 | 10.80M |
| March 31, 2022 | 9.543M |
| December 31, 2021 | 8.701M |
| September 30, 2021 | 8.673M |
| June 30, 2021 | 8.154M |
| March 31, 2021 | 7.568M |
| December 31, 2020 | 7.921M |
| September 30, 2020 | 6.769M |
| Date | Value |
|---|---|
| June 30, 2020 | 8.953M |
| March 31, 2020 | 10.22M |
| December 31, 2019 | 10.82M |
| September 30, 2019 | 12.40M |
| June 30, 2019 | 11.78M |
| March 31, 2019 | 12.21M |
| December 31, 2018 | 12.51M |
| September 30, 2018 | 12.16M |
| June 30, 2018 | 12.48M |
| March 31, 2018 | 12.64M |
| December 31, 2017 | 12.77M |
| September 30, 2017 | 13.04M |
| June 30, 2017 | 12.82M |
| March 31, 2017 | 13.54M |
| December 31, 2016 | 14.00M |
| September 30, 2016 | 13.69M |
| June 30, 2016 | 12.74M |
| March 31, 2016 | 11.64M |
| December 31, 2015 | 8.883M |
| September 30, 2015 | 7.894M |
| June 30, 2015 | 5.742M |
| March 31, 2015 | 2.554M |
| December 31, 2014 | 1.577M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Innoviva, Inc. | 126.42M |
| Collegium Pharmaceutical, Inc. | 327.69M |
| Johnson & Johnson | 25.14B |
| Ligand Pharmaceuticals, Inc. | 103.43M |
| Harrow, Inc. | 175.69M |